These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 14722212)

  • 1. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
    Foell D; Frosch M; Schulze zur Wiesch A; Vogl T; Sorg C; Roth J
    Ann Rheum Dis; 2004 Feb; 63(2):206-8. PubMed ID: 14722212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis.
    Schulze zur Wiesch A; Foell D; Frosch M; Vogl T; Sorg C; Roth J
    Clin Exp Rheumatol; 2004; 22(3):368-73. PubMed ID: 15144135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
    Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
    JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
    Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
    Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.
    Moncrieffe H; Ursu S; Holzinger D; Patrick F; Kassoumeri L; Wade A; Roth J; Wedderburn LR
    Rheumatology (Oxford); 2013 Aug; 52(8):1467-76. PubMed ID: 23620557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
    Kane D; Roth J; Frosch M; Vogl T; Bresnihan B; FitzGerald O
    Arthritis Rheum; 2003 Jun; 48(6):1676-85. PubMed ID: 12794836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation.
    Wulffraat NM; Haas PJ; Frosch M; De Kleer IM; Vogl T; Brinkman DM; Quartier P; Roth J; Kuis W
    Ann Rheum Dis; 2003 Mar; 62(3):236-41. PubMed ID: 12594109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.
    Holzinger D; Frosch M; Kastrup A; Prince FH; Otten MH; Van Suijlekom-Smit LW; ten Cate R; Hoppenreijs EP; Hansmann S; Moncrieffe H; Ursu S; Wedderburn LR; Roth J; Foell D; Wittkowski H
    Ann Rheum Dis; 2012 Jun; 71(6):974-80. PubMed ID: 22267331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.
    Patro PS; Singh A; Misra R; Aggarwal A
    J Rheumatol; 2016 Apr; 43(4):731-7. PubMed ID: 26834220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial.
    Alexeeva E; Horneff G; Dvoryakovskaya T; Denisova R; Nikishina I; Zholobova E; Malievskiy V; Santalova G; Stadler E; Balykova L; Spivakovskiy Y; Kriulin I; Alshevskaya A; Moskalev A
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):5. PubMed ID: 33407590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
    Sumner EJ; Almeida B; Palman J; Bale P; Heard C; Holzinger D; Roth J; Foell D; Robinson E; Ursu S; Wallace C; Gilmour K; Wedderburn LR; Ralph E
    Clin Rheumatol; 2022 Sep; 41(9):2825-2830. PubMed ID: 35486225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
    Yamasaki Y; Takei S; Imanaka H; Nerome Y; Kubota T; Nonaka Y; Akaike H; Takezaki T; Kawano Y
    Mod Rheumatol; 2016 Jul; 26(4):551-6. PubMed ID: 26474088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
    Gerss J; Roth J; Holzinger D; Ruperto N; Wittkowski H; Frosch M; Wulffraat N; Wedderburn L; Stanevicha V; Mihaylova D; Harjacek M; Len C; Toppino C; Masi M; Minden K; Saurenmann T; Uziel Y; Vesely R; Apaz MT; Kuester RM; Elorduy MJ; Burgos-Vargas R; Ioseliani M; Magni-Manzoni S; Unsal E; Anton J; Balogh Z; Hagelberg S; Mazur-Zielinska H; Tauber T; Martini A; Foell D;
    Ann Rheum Dis; 2012 Dec; 71(12):1991-7. PubMed ID: 22689317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Klotsche J; Minden K; Niewerth M; Horneff G
    Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
    Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic D; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Hamilton S; Johnson A; Huang B; Lovell DJ;
    Arthritis Rheum; 2012 Jun; 64(6):2012-21. PubMed ID: 22183975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis.
    Rothmund F; Gerss J; Ruperto N; Däbritz J; Wittkowski H; Frosch M; Wulffraat NM; Wedderburn LR; Holzinger D; Gohar F; Vastert SJ; Brik R; Deslandre CJ; Melo-Gomes JA; Saad Magalhaes C; Barcellona R; Russo R; Gattorno M; Martini A; Roth J; Foell D;
    Arthritis Care Res (Hoboken); 2014 Jun; 66(6):949-55. PubMed ID: 24339418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.
    Gottlieb BS; Keenan GF; Lu T; Ilowite NT
    Pediatrics; 1997 Dec; 100(6):994-7. PubMed ID: 9374571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.